These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 37919691)

  • 21. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy.
    Davis JA; Gaffney KJ; McGann M; Smith D; Edwards K; Baldino E; Bakos K; Butcher C; Greenwell B; Hess BT; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e14-e18. PubMed ID: 36319568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy.
    Dong R; Jiang S; Chen Y; Ma Y; Sun L; Xing C; Zhang S; Yu K
    J Interferon Cytokine Res; 2021 Dec; 41(12):469-476. PubMed ID: 34935483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
    Shalabi H; Sachdev V; Kulshreshtha A; Cohen JW; Yates B; Rosing DR; Sidenko S; Delbrook C; Mackall C; Wiley B; Lee DW; Shah NN
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32883871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
    Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
    J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine Release Syndrome after Chimeric Antigen Receptor Transduced T-Cell Therapy in Cancers: A Systematic Review.
    Taheri S
    Saudi J Kidney Dis Transpl; 2022 Nov; 33(6):795-823. PubMed ID: 38018721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
    Read JA; Rouce RH; Mo F; Mamonkin M; King KY
    Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC].
    Tudesq JJ; Yakoub-Agha M; Bay JO; Courbon C; Paul F; Picard M; Pochon C; Sterin A; Vicente C; Canet E; Yakoub-Agha I; Moreau AS
    Bull Cancer; 2023 Feb; 110(2S):S116-S122. PubMed ID: 34895696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma.
    Barata A; Hoogland AI; Kommalapati A; Logue J; Welniak T; Hyland KA; Eisel SL; Small BJ; Jayani RV; Booth-Jones M; Oswald LB; Gonzalez BD; Kirtane KS; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
    Transplant Cell Ther; 2022 Jul; 28(7):401.e1-401.e7. PubMed ID: 35580732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies.
    Xu QW; Xu H; Xue L; Wang L; Zhang XH; Song KD; Yao W; Wan X; Tong J; Liu HL; Liu X; Zhu XY; Sun ZM; Wang XB
    Transfus Apher Sci; 2022 Dec; 61(6):103473. PubMed ID: 35672235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.
    Perez A; Al Sagheer T; Nahas GR; Linhares YPL
    Front Immunol; 2024; 15():1412002. PubMed ID: 38779668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
    Lyu Y; Zhang M; Wei G; Ding S; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):137-143. PubMed ID: 36161296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.
    Hoogland AI; Barata A; Logue J; Kommalapati A; Hyland KA; Nelson AM; Eisel SL; Small BJ; James BW; Christy SM; Bulls HW; Booth-Jones M; Jayani RV; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
    Transplant Cell Ther; 2022 Jun; 28(6):305.e1-305.e9. PubMed ID: 35378330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2].
    Xu XZ; Liu R; Zhao WH; Yang Y; Liu J; Zhang WG; Bai J; He AL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):838-844. PubMed ID: 38049336
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.
    Schroeder T; Martens T; Fransecky L; Valerius T; Schub N; Pott C; Baldus C; Stölzel F
    Intensive Care Med; 2024 Sep; 50(9):1459-1469. PubMed ID: 39172238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients - A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts.
    Tomasik J; Avni B; Grisariu S; Elias S; Zimran E; Stepensky P; Basak GW
    Arch Immunol Ther Exp (Warsz); 2024 Jan; 72(1):. PubMed ID: 39277881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies.
    Pu LF; Zheng HM; Feng XJ; Charwudzi A; Liang X; Hu LH; Ding YY; Liu ZL; Liao Y; Xiong SD
    J Transl Med; 2024 Jul; 22(1):613. PubMed ID: 38956649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
    Luan C; Zhou J; Wang H; Ma X; Long Z; Cheng X; Chen X; Huang Z; Zhang D; Xia R; Ge J
    Front Immunol; 2021; 12():707191. PubMed ID: 34349766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.